Horizon Europe (2021 - 2027)

Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensing: ReLiV

Last update: May 23, 2024 Last update: May 23, 2024


Start Date:May 1, 2024
End Date:Apr 30, 2027
Contract value: EUR 2,499,875
Sectors:Health, Science & Innovation Health, Science & Innovation
Date posted:May 23, 2024

Associated funding

Associated experts


Programme(s): HORIZON.3.1 - The European Innovation Council (EIC) 

Topic(s): HORIZON-EIC-2023-TRANSITIONCHALLENGES-01 - EIC Transition Challenge: Full scale Micro-Nano-Bio devices for medical and medical research applications

Call for proposal: HORIZON-EIC-2023-TRANSITION-01

Funding Scheme: HORIZON-EIC - HORIZON EIC Grants

Grant agreement ID: 101158688


The analysis of volatile organic compounds (VOCs) in exhaled breath with nano sensors has great potential to transform healthcare, with accurate, inexpensive, realtime diagnostics. However, attempts to implement this strategy have failed to reach clinical deployment. Firstly, many efforts try to identify the complex mixture of VOCs associated with disease, which is a long and expensive process. Secondly, commercially available sensors require high operating temperatures and have low sensitivity to breath VOCs. NaNose Medical has overcome these limitations through DiaNose, an easy to use, hand-held diagnostics device with potential applicability in >20 different diseases. Instead of identifying individual VOCs, DiaNose deploys an array of patented cross-reactive sensors delivering a chemical signature of breath that can be classified as healthy or diseased through artificial intelligence. Our initial alpha prototype focuses on a key clinical indication: Non-Alcoholic Fatty Liver Disease (NAFLD): with a global prevalence of 30%, it is the leading cause of liver related morbidity, generating an annual burden in Europe of > €35 billion and a further €200 billion of societal costs. Crucially, NAFLD diagnostics present key limitations: liver biopsies are expensive, invasive and subject to sampling error, and non-invasive alternatives lack precision, are operator-dependent, and require expert interpretation. DiaNose will fill this gap, aiming to achieve a diagnostic accuracy of >90% at <50€/test. Lab testing of our alpha prototype has shown high accuracy (88%) with NAFLD models. With the ReLiV project, we will develop an advanced beta prototype that will be validated in clinical settings across different locations. This will bring DiaNose one step closer to commercialization, providing a truly costeffective, point-of-care detection and monitoring device capable of improving patient outcomes and alleviating the economic burden generated by the growing NAFLD pandemic.

Want to unlock full information?
Member-only information. Become a member to access projects awards, find the right consortia partners, subcontractors and more.